Important Mechanism of Action of Tirzepatide before Using

Important Mechanism of Action of Tirzepatide before Using -By Polypeptide.ltd

Authoritative source：PubChem

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

Mechanism of action of Tirzepatide Tirzepatide peptide is a dual agonist of hormone receptors known as GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). These hormones are produced naturally in the body and they play an important role in regulating blood sugar levels and metabolism.

Stimulates insulin release Tirzepatide activates GIP receptors and GLP-1 receptors, both of which are located on pancreatic beta cells, thereby stimulating insulin release. As a result of activation of these receptors, the pancreas releases insulin in response to high blood sugar. Insulin lowers blood sugar levels because it helps cells absorb glucose from the blood.

Inhibition of Glucagon Release Tirzepatide also inhibits the release of glucagon, another hormone produced by the pancreas.

Glucagon raises blood sugar levels by promoting the release of stored glucose from the liver. By reducing glucagon release, tirzepatide helps prevent excessive glucose production.

Appetite Regulation and Gastric Emptying GLP-1 receptors are also found in areas of the brain involved in appetite regulation. Activation of these receptors by tirzepatide can help reduce food intake and promote a feeling of fullness.

Additionally, GLP-1 slows down gastric emptying, which can help control the rate at which nutrients, including glucose, are absorbed into the bloodstream after eating.

Weight Loss Tirzepatide’s dual agonist action on both GIP and GLP-1 receptors has been associated with significant weight loss. It may work by modulating fat utilization and promoting a sense of fullness, leading to reduced calorie intake and increased energy expenditure.

By activating GIP and GLP-1 receptors, tirzepatide addresses multiple aspects of blood sugar regulation, insulin release, glucagon inhibition, and appetite control.

Reference citations [1] Ahangarpour M, Kavianinia I, Harris PW, Brimble MA (January 2021). "Photo-induced radical thiol-ene chemistry: a versatile toolbox for peptide-based drug design". Chemical Society Reviews.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

Royal Society of Chemistry.

898–944. doi:10.1039/d0cs00354a. PMID 33404559. S2CID 230783854.

50

(2):

[2] "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023.

Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

[3] Jump up to:a b c d e f g h i j k l "Drug Trials Snapshots: Mounjaro". U.S. Food and Drug Administration (FDA). 13 June 2023. Retrieved 14 June 2023. This article incorporates text from this source, which is in the public domain.

[4] Dutta D, Surana V, Singla R, Aggarwal S, Sharma M (November–December 2021). "Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis". Indian Journal of Endocrinology and Metabolism. 25 (6): 475–489. doi:10.4103/ijem.ijem_423_21. PMC 8959203. PMID 35355921.

[5] Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. (4 June 2022). "Tirzepatide Once Weekly for the Treatment of Obesity". NEJM. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID 35658024. S2CID 249385412. Archived from the original on 5 June 2022. Retrieved 6 June 2022.

[6] "Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes". Business Insider. RTTNews. 19 October 2021. Archived from the original on 28 October 2021. Retrieved 28 October 2021.

[7] Kellaher, Colin (28 April 2022). "Eli Lilly's Tirzepatide Meets Main Endpoints in Phase 3 Obesity Study". MarketWatch. Dow Jones Newswires. Archived from the original on 29 April 2022.

Retrieved 29 April 2022.

[8] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.

(August 2021). "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes".

The New England Journal of Medicine.

385 (6): 503–515. doi:10.1056/NEJMoa2107519. PMID 34170647. S2CID 235635529.

[9] Dee, Jane E. (6 June 2022). "More Than 20% Weight Reduction in Individuals With Obesity". Yale Department of Internal Medicine. Archived from the original on 10 June 2022.

Retrieved 12 June 2022.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

[10] Davis, Nicola (5 June 2022). "Diabetes drug leads to notable weight loss in people with obesity – study". The Guardian. Archived from the original on 11 June 2022. Retrieved 12 June 2022.

[11] World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.

[12] Jump up to:a b c "Mounjaro EPAR". European Medicines Agency (EMA). 18 July 2022. Archived from the original on 12 December 2022. Retrieved 2 January 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[13] Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G (November 2022).

"Tirzepatide: A Systematic Update".

Int J Mol Sci. 23 (23). doi:10.3390/ijms232314631. PMC 9741068. PMID 36498958.

[14] "Mounjaro: Pending EC decision". European Medicines Agency. 22 July 2022. Archived from the original on 28 July 2022. Retrieved 30 July 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[15] "Mounjaro Product information". Union Register of medicinal products. Archived from the original on 8 February 2023. Retrieved 3 March 2023.

[16] "Drug and Health Product Submissions Under Review (SUR): New drug submissions completed". Health Canada. 10 March 2021. Archived from the original on 5 January 2023.

Retrieved 5 January 2023.

[17] Jump up to:a b Min T, Bain SC (January 2021). "The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials". Diabetes Therapy. 12 (1): 143–157. doi:10.1007/s13300-020-00981-0. PMC 7843845. PMID 33325008.

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/